Meta-analysis confirms CBD reduces seizures in Dravet syndrome
A meta-analysis of three randomized trials found adjunctive CBD increased the chance of achieving 50% seizure reduction by 69% in Dravet syndrome patients.
Quick Facts
What This Study Found
Pooling three RCTs with 359 participants (228 CBD, 131 placebo), adjunctive CBD was associated with a 69% higher likelihood of achieving 50% or greater reduction in convulsive seizures (RR 1.69, 95% CI 1.21-2.36, p=0.002). However, CBD also led to higher treatment discontinuation (RR 3.12) and side effects including somnolence, decreased appetite, diarrhea, and elevated liver enzymes.
Key Numbers
3 RCTs; 359 participants; 50% responder rate RR 1.69 (p=0.002); treatment discontinuation RR 3.12; common AEs: somnolence, appetite decrease, diarrhea, elevated liver enzymes.
How They Did This
Systematic review and meta-analysis of three randomized, placebo-controlled, double-blind trials of plant-derived pharmaceutical CBD (Epidiolex) as adjunctive treatment for Dravet syndrome seizures.
Why This Research Matters
Dravet syndrome is among the most severe drug-resistant epilepsies. This meta-analysis provides the highest level of evidence confirming that CBD offers meaningful seizure reduction for these patients.
The Bigger Picture
This meta-analysis helped solidify the evidence base that led to regulatory approval of CBD for Dravet syndrome in multiple countries. It represents one of the clearest success stories for cannabinoid medicine.
What This Study Doesn't Tell Us
Only three trials available; relatively short treatment periods; all used the same pharmaceutical CBD formulation (Epidiolex), so results may not generalize to other CBD products.
Questions This Raises
- ?Can longer treatment maintain seizure reduction?
- ?How do liver enzyme elevations change with prolonged use?
Trust & Context
- Key Stat:
- 69% higher chance of 50%+ seizure reduction with CBD (RR 1.69)
- Evidence Grade:
- Strong: meta-analysis of three randomized, placebo-controlled, double-blind trials.
- Study Age:
- Published 2020.
- Original Title:
- Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.
- Published In:
- CNS drugs, 34(3), 229-241 (2020)
- Authors:
- Lattanzi, Simona(5), Brigo, Francesco(4), Trinka, Eugen(4), Zaccara, Gaetano, Striano, Pasquale, Del Giovane, Cinzia, Silvestrini, Mauro
- Database ID:
- RTHC-02673
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How much does CBD reduce seizures in Dravet syndrome?
Patients on CBD were 69% more likely to achieve at least 50% seizure reduction compared to placebo (RR 1.69, p=0.002).
What are the main side effects?
Somnolence, decreased appetite, diarrhea, and elevated liver enzymes. Treatment was discontinued in 9% of CBD patients vs. 2.3% on placebo.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02673APA
Lattanzi, Simona; Brigo, Francesco; Trinka, Eugen; Zaccara, Gaetano; Striano, Pasquale; Del Giovane, Cinzia; Silvestrini, Mauro. (2020). Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.. CNS drugs, 34(3), 229-241. https://doi.org/10.1007/s40263-020-00708-6
MLA
Lattanzi, Simona, et al. "Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.." CNS drugs, 2020. https://doi.org/10.1007/s40263-020-00708-6
RethinkTHC
RethinkTHC Research Database. "Adjunctive Cannabidiol in Patients with Dravet Syndrome: A S..." RTHC-02673. Retrieved from https://rethinkthc.com/research/lattanzi-2020-adjunctive-cannabidiol-in-patients
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.